Galectin Therapeutics Inc. Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 29.98. In total, the insiders bought 4 505 403 and sold 2 289 317 GALT shares in the last 100 trades.

Insider Power

(Last 100 transactions)
29.98
Buy 4 505 403 Shares
Sell 2 289 317 Shares

Historical Insider Trades

Date Type Action Person Amount
Oct 23, 2024 Common Stock Buy Eldred Kary 500
Oct 17, 2024 Common Stock Buy Freeman Kevin D 1 300
Oct 16, 2024 Common Stock Buy Freeman Kevin D 5 000
Oct 16, 2024 Common Stock Buy Freeman Kevin D 5 000
Aug 23, 2024 Common Stock Buy Zordani Richard A. Jr. 1 759
Aug 23, 2024 Common Stock Buy Zordani Richard A. Jr. 1 000
Aug 22, 2024 Common Stock Buy Zordani Richard A. Jr. 741
Aug 02, 2024 Common Stock Option (right to buy) Buy Jamil Khurram 150 000
Aug 02, 2024 Restricted Stock Unit Buy Jamil Khurram 30 000
Aug 01, 2024 Stock Option (right to buy) Buy Jamil Khurram 100 000
Aug 01, 2024 Restricted Stock Unit Buy Jamil Khurram 10 000
Jul 22, 2024 Common Stock Buy Eldred Kary 400
Jun 20, 2024 Common Stock Buy Freeman Kevin D 2 500
Apr 30, 2024 Common Stock Buy Zordani Richard A. Jr. 1 000
Apr 24, 2024 Common Stock Buy Lewis Joel 1 000
Apr 23, 2024 Common Stock Sell Czirr James C 3 677
Apr 22, 2024 Common Stock Sell Czirr James C 21 323
Apr 22, 2024 Common Stock Buy Freeman Kevin D 2 500
Apr 09, 2024 Common Stock Buy Freeman Kevin D 2 063
Mar 01, 2024 Common Stock Sell Lewis Joel 152 584
Jan 24, 2024 Stock Option (right to buy) Buy Zordani Richard A. Jr. 50 000
Jan 24, 2024 Common Stock Buy Uihlein Richard E 23 256
Jan 24, 2024 Stock Option (right to buy) Buy Uihlein Richard E 50 000
Jan 24, 2024 Stock Option (right to buy) Buy Schwartz Elissa J. 50 000
Jan 24, 2024 Stock Option (right to buy) Buy Rubin Marc 50 000
Click to get the best stock tips daily for free!
ABOUT GALECTIN THERAPEUTICS INC.
Galectin Therapeutics.
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatiti...
GOLDEN STAR
Ticker Change Signal Date
NYT
$54.61
2.98% Dec 04
V
VCSH
$78.49
0.140% Dec 04
V
VGSH
$58.30
0.103% Dec 04
S
SLQD
$49.95
0.160% Dec 04
I
ISTB
$48.00
0.208% Dec 04

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE